Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Valacyclovir
Generic Name
Valacyclovir
Active Ingredient
ValacyclovirCategory
Other
Salt Form
Hydrochloride
Variants
44
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 1000 mg/1 | TABLET | ORAL | 72189-594 |
| 1000 mg/1 | TABLET | ORAL | 50090-7484 |
| 500 mg/1 | TABLET | ORAL | 69367-262 |
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Valacyclovir, you must consult a qualified healthcare professional.
| 1000 mg/1 | TABLET | ORAL | 70518-4100 |
| 500 mg/1 | TABLET | ORAL | 82804-009 |
| 500 mg/1 | TABLET, FILM COATED | ORAL | 31722-704 |
| 500 mg/1 | TABLET | ORAL | 62135-613 |
| 1 g/1 | TABLET, FILM COATED | ORAL | 68071-4805 |
| 1 g/1 | TABLET, FILM COATED | ORAL | 71335-0630 |
| 500 mg/1 | TABLET, FILM COATED | ORAL | 82009-040 |
| 1000 mg/1 | TABLET | ORAL | 50090-7270 |
| 1 g/1 | TABLET, FILM COATED | ORAL | 67296-1297 |
+ 31 more variants
Detailed information about Valacyclovir
Valacyclovir is a potent antiviral medication used to treat infections caused by herpes viruses, including shingles, cold sores, and genital herpes. It belongs to the nucleoside analogue class and acts as a prodrug to acyclovir.
Dosage regimens for valacyclovir vary significantly based on the condition being treated. Healthcare providers typically utilize the following standard guidelines for immunocompetent adults:
Valacyclovir is approved for specific uses in children, with dosing often based on body weight:
Because valacyclovir is primarily eliminated by the kidneys, dosage adjustments are mandatory for patients with reduced renal function to prevent drug accumulation and toxicity. Healthcare providers will calculate the Creatinine Clearance (CrCl) to determine the appropriate dose. For example, in shingles treatment, if CrCl is between 30-49 mL/min, the dose may be reduced to 1 gram every 12 hours; if CrCl is below 10 mL/min, the dose may be 500 mg once every 24 hours.
Dosage adjustments are generally not required for patients with mild to moderate hepatic impairment (cirrhosis), as the conversion of valacyclovir to acyclovir is robust. However, clinical data in severe hepatic impairment is limited, and such patients should be monitored closely.
Geriatric patients are more likely to have reduced renal function and are at a higher risk for central nervous system (CNS) side effects. Dose selection should be cautious, usually starting at the lower end of the dosing range, and renal function should be assessed before and during treatment.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular schedule. Do not 'double up' or take two doses at once to make up for a missed one.
Signs of a valacyclovir overdose may include acute renal failure (sudden loss of kidney function), confusion, hallucinations, agitation, and decreased consciousness. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Hemodialysis may be used to remove acyclovir from the blood in severe cases.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication early without medical guidance, even if symptoms improve.
Most patients tolerate valacyclovir well; however, some side effects occur frequently. These are generally mild and often resolve as the body adjusts to the medication:
Valacyclovir is a powerful antiviral, but it must be used with caution in several clinical scenarios. The most critical safety consideration is the maintenance of adequate hydration. Because the active metabolite, acyclovir, is excreted through the kidneys, it can crystallize in the renal tubules if the urine is too concentrated. This can lead to obstructive uropathy and acute kidney injury. Patients should be instructed to maintain a high fluid intake throughout the duration of their treatment.
Another vital safety point is the timing of therapy. Valacyclovir is most effective when started as soon as possible after the onset of symptoms. For shingles, this is within 72 hours; for genital herpes, within 48 hours. Delaying treatment significantly reduces the clinical benefit of the medication.
As of 2026, there are no FDA black box warnings for Valacyclovir. It is considered a safe and well-tolerated medication for the vast majority of the population when used according to established dosing guidelines.
While valacyclovir has few absolute contraindications regarding drug combinations, the following should be avoided:
Valacyclovir is strictly contraindicated in the following circumstances:
These are conditions where the risk may outweigh the benefit, or where extreme caution and dose adjustment are required:
Valacyclovir is classified as a Pregnancy Category B medication under the old FDA system, meaning animal studies have failed to demonstrate a risk to the fetus, and there are no adequate, well-controlled studies in pregnant women. However, extensive clinical experience and pregnancy registries have not shown an increased risk of major birth defects compared to the general population.
In late pregnancy, healthcare providers often prescribe valacyclovir suppressively (usually starting at 36 weeks gestation) to women with a history of genital herpes. This is done to reduce the likelihood of an active outbreak at the time of delivery, thereby decreasing the need for a Cesarean section and protecting the newborn from neonatal herpes, which can be fatal.
Acyclovir, the active metabolite of valacyclovir, is excreted in human breast milk. Following oral administration of valacyclovir, acyclovir concentrations in breast milk can be significantly higher than those in the mother's plasma. However, acyclovir is frequently used directly in newborns to treat neonatal herpes at much higher doses than what an infant would receive through breast milk. Valacyclovir is generally considered compatible with breastfeeding, but the decision should be made in consultation with a pediatrician.
Valacyclovir is a prodrug of the acyclic purine nucleoside analogue acyclovir. Its primary molecular target is the viral DNA polymerase enzyme. The process begins with the conversion of valacyclovir to acyclovir by intestinal and hepatic esterases. Once inside a virus-infected cell, acyclovir is phosphorylated to acyclovir monophosphate by viral thymidine kinase. This is the 'selectivity' step; the drug is only activated in cells where the virus is present. Subsequent phosphorylation by cellular kinases creates acyclovir triphosphate. This molecule then competes with natural deoxyguanosine triphosphate (dGTP) for incorporation into viral DNA. Once incorporated, it causes obligate chain termination, effectively stopping the virus from building its DNA and replicating.
The antiviral activity of valacyclovir is highly specific to the Herpes Simplex Virus types 1 and 2 (HSV-1, HSV-2), Varicella-Zoster Virus (VZV), and to a lesser extent, Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV). The relationship between the concentration of the drug in the blood and its effect is well-established; higher peak concentrations achieved by valacyclovir (compared to acyclovir) result in more effective suppression of viral replication. Tolerance to the medication does not typically develop, though viral resistance can occur in severely immunocompromised patients through mutations in the viral thymidine kinase gene.
Common questions about Valacyclovir
Valacyclovir is an antiviral medication primarily used to treat infections caused by the herpes family of viruses. This includes herpes zoster (shingles) in adults, as well as herpes labialis (cold sores) in both adults and children over 12. It is also a mainstay treatment for genital herpes, used to treat initial outbreaks, recurrent episodes, and as a daily suppressive therapy to prevent future outbreaks. Additionally, it is used to treat chickenpox in children aged 2 to 18. While it effectively manages symptoms and speeds up healing, it does not cure the underlying viral infection.
The most frequently reported side effects of valacyclovir are headache, nausea, and abdominal pain. Many patients find that these symptoms are mild and tend to decrease as their body becomes accustomed to the medication. Some individuals may also experience dizziness, fatigue, or a mild skin rash. Taking the tablets with food and staying well-hydrated can often help minimize gastrointestinal upset. If side effects become severe or persistent, it is important to consult your healthcare provider to discuss a possible dosage adjustment.
There is no known direct chemical interaction between alcohol and valacyclovir that would make the drug ineffective. However, healthcare providers generally advise against heavy alcohol consumption while taking this medication. Alcohol can lead to dehydration, which increases the risk of valacyclovir-related kidney strain. Furthermore, alcohol may worsen certain side effects of the drug, such as dizziness, headache, and nausea. To ensure the safest and most effective treatment, it is best to limit alcohol intake and focus on drinking plenty of water.
Valacyclovir is generally considered safe for use during pregnancy when the benefits outweigh the potential risks. Extensive data from pregnancy registries have not shown an increased risk of birth defects in infants whose mothers took the drug. In fact, many doctors prescribe valacyclovir suppressively starting at 36 weeks of pregnancy to prevent a herpes outbreak during delivery, which protects the baby from neonatal herpes. However, because every pregnancy is unique, you should only take valacyclovir under the direct supervision of your obstetrician. They will weigh your specific medical history against the clinical data available.
The time it takes for valacyclovir to work depends on the condition being treated and how quickly the medication was started. For cold sores, many patients notice a reduction in tingling and pain within 24 hours of taking the one-day treatment. For shingles or genital herpes outbreaks, symptoms like pain and itching usually begin to improve within 2 to 3 days. However, the full course of medication must be completed to ensure the virus is adequately suppressed. It is most effective when taken at the very first sign of an outbreak, such as a tingling sensation.
Yes, valacyclovir can be stopped suddenly without causing a withdrawal syndrome or physical dependence. However, if you are taking the medication for suppressive therapy (to prevent outbreaks), stopping the drug will likely result in your outbreaks returning to their original frequency. If you are taking it to treat an active infection like shingles, stopping early may allow the virus to continue replicating, potentially leading to a longer recovery or increased pain. You should always discuss your reasons for wanting to stop the medication with your healthcare provider first.
If you miss a dose of valacyclovir, you should take it as soon as you remember. If it is almost time for your next scheduled dose, simply skip the missed dose and resume your regular dosing schedule. It is important not to take two doses at the same time to 'catch up,' as this can increase the risk of side effects like headache or nausea. Consistency is key to maintaining enough of the drug in your system to fight the virus. Setting a daily alarm can be a helpful way to ensure you take your doses on time.
Weight gain is not a recognized or common side effect of valacyclovir based on clinical trials and post-marketing surveillance. The medication does not affect the metabolic processes or hormonal balances typically associated with drug-induced weight changes. If you experience sudden or unexplained weight gain while taking valacyclovir, it is more likely related to other factors, such as changes in diet, activity levels, or other underlying medical conditions. You should report any significant weight changes or unusual swelling (edema) to your doctor, as swelling can sometimes indicate kidney issues.
Valacyclovir can be taken with many other medications, but some interactions require caution. It should be used carefully with other drugs that can affect the kidneys, such as NSAIDs (ibuprofen, naproxen) or certain antibiotics. Drugs like probenecid and cimetidine can increase the levels of valacyclovir in your blood, which may increase the risk of side effects. It is also important to avoid live virus vaccines while taking antivirals. Always provide your healthcare provider and pharmacist with a complete list of all prescription drugs, over-the-counter medicines, and supplements you are currently taking.
Yes, valacyclovir is widely available as a generic medication, which is typically much more affordable than the brand-name version, Valtrex. Generic valacyclovir is required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. It must also prove 'bioequivalence,' meaning it works in the body in the same way and over the same amount of time. Most insurance plans prefer the generic version. You can consult your pharmacist to ensure you are receiving the most cost-effective version of the medication.
Other drugs with the same active ingredient (Valacyclovir)
While rare, some side effects of valacyclovir are life-threatening and require emergency intervention:
> Warning: Stop taking Valacyclovir and call your doctor immediately if you experience any of these serious symptoms.
For patients on long-term suppressive therapy (taking the drug daily for years), valacyclovir has shown a remarkably safe profile. There is no evidence that the virus develops significant resistance in immunocompetent individuals during long-term use. However, periodic monitoring of renal function is recommended to ensure the kidneys continue to clear the drug effectively over time. Some patients may experience a gradual thinning of hair (alopecia), though this is rare and typically reversible upon discontinuation.
No FDA black box warnings for Valacyclovir. Unlike some other antiviral or immunosuppressant medications, valacyclovir does not carry the FDA’s most severe warning level. However, the warnings regarding TTP/HUS in immunocompromised patients and the risk of renal failure serve as the primary safety focal points for clinicians.
Report any unusual symptoms or persistent side effects to your healthcare provider to ensure your treatment plan remains safe and effective.
For most healthy patients taking a short course of valacyclovir (e.g., for cold sores or a single shingles outbreak), routine lab monitoring is not strictly required. However, for specific groups, the following may be necessary:
Valacyclovir may cause dizziness, confusion, or fatigue in some individuals. Patients should assess their reaction to the medication before driving, operating heavy machinery, or engaging in potentially dangerous activities. If CNS side effects occur, these activities should be avoided entirely.
There is no direct chemical interaction between valacyclovir and alcohol. However, alcohol can cause dehydration and may exacerbate side effects like dizziness and nausea. Because hydration is vital for kidney safety while on valacyclovir, excessive alcohol consumption is discouraged during treatment.
Valacyclovir does not require a tapering schedule and does not cause a withdrawal syndrome. However, stopping suppressive therapy will likely result in a return to the patient's baseline frequency of herpes outbreaks. If you are taking the drug to prevent transmission to a partner, stopping the medication will increase the risk of viral shedding and transmission.
> Important: Discuss all your medical conditions, especially any history of kidney disease or immune system disorders, with your healthcare provider before starting Valacyclovir.
Valacyclovir does not typically interfere with standard laboratory test results. However, it may cause a false increase in serum creatinine if certain older laboratory methods are used. It is always prudent to inform laboratory staff of all medications you are taking.
Most interactions with valacyclovir occur via renal clearance competition. Because acyclovir is actively secreted into the urine via organic anion transporters (OATs), any drug that also uses these transporters can slow down the 'exit' of valacyclovir from the body. This leads to increased toxicity rather than reduced efficacy.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those purchased without a prescription.
There is a high degree of cross-sensitivity between valacyclovir and other nucleoside analogues. Patients who have had severe reactions to famciclovir or ganciclovir should be evaluated by an allergist before starting valacyclovir, as the underlying chemical 'nucleoside' structure may be the trigger for the immune response.
Furthermore, patients should be aware that 'inactive ingredients' in the tablet (such as povidone, magnesium stearate, or FD&C Blue #2) can occasionally cause reactions. If you have known allergies to specific food dyes or tablet fillers, review the full ingredient list with your pharmacist.
> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before prescribing Valacyclovir to ensure it is the safest option for you.
Valacyclovir is FDA-approved for:
Safety and effectiveness have not been established for other uses in pediatric patients (such as genital herpes suppression in children). Dosing must be carefully calculated based on weight to avoid renal toxicity.
Patients over the age of 65 are at a higher risk for adverse events when taking valacyclovir. This is primarily due to the natural age-related decline in kidney function. Elderly patients are significantly more prone to CNS side effects, such as confusion, hallucinations, and somnolence (extreme sleepiness). It is essential that the dose be adjusted based on the patient's measured renal function rather than just their age.
Renal impairment is the most significant factor affecting valacyclovir safety. The drug's half-life increases from ~3 hours to up to 14 hours in patients with end-stage renal disease. Dose intervals must be extended (e.g., from three times daily to once daily or even once every 48 hours) depending on the severity of the impairment. For patients on hemodialysis, the dose should be administered after the dialysis session, as the procedure removes approximately 60% of the drug from the blood.
In patients with moderate cirrhosis, the rate but not the extent of conversion from valacyclovir to acyclovir is reduced. Because the total amount of active drug available (AUC) remains unchanged, dosage adjustments are generally not necessary for patients with liver disease. However, these patients should still be monitored for general tolerability.
> Important: Special populations require individualized medical assessment and frequent monitoring to ensure the safest possible treatment outcome.
| Parameter | Value |
|---|---|
| Bioavailability | ~54% (as Acyclovir) |
| Protein Binding | 13.5% to 17.9% |
| Half-life | 2.5 to 3.3 hours (Normal Renal) |
| Tmax | 1.0 to 2.0 hours |
| Metabolism | Valacyclovir Hydrolase (Hepatic/Intestinal) |
| Excretion | Renal (89%) |
Valacyclovir is categorized as a nucleoside analogue antiviral. It belongs to the same therapeutic family as acyclovir, famciclovir, and penciclovir. Within the broader landscape of infectious disease, it is considered a 'purine' analogue because its structure mimics guanosine, one of the four essential building blocks of DNA.